hero section gradient
16 handpicked stocks

AI & Big Data for Government

These carefully selected companies are leading the digital transformation within federal agencies. Analysts are watching this space closely as government spending on AI and data technology continues to grow, potentially creating long-term investment opportunities.

Author avatar

Han Tan | Market Analyst

Published on July 1

Your Basket's Financial Footprint

Summary of total market capitalisation and breakdown for the AI & Big Data for Government basket.

Key Takeaways for Investors:
  • Large-cap dominance suggests lower volatility and market-like returns, likely offering greater stability than small-cap-heavy baskets.
  • Suitable as a core holding in a diversified portfolio, not a vehicle for speculative, short-term trades.
  • Expect steady, long-term appreciation rather than explosive short-term gains; growth tends to be gradual.
Total Market Cap
  • PLTR: $430.42B

  • ACN: $155.35B

  • BAH: $12.40B

  • Other

About This Group of Stocks

1

Our Expert Thinking

Government agencies are rapidly adopting AI and data analytics to enhance national security and operational efficiency. This major shift is supported by substantial, long-term federal budgets dedicated to technological modernization, creating a durable growth trajectory for companies in this space.

2

What You Need to Know

This collection spans the entire government tech ecosystem – from data analytics platforms and cybersecurity providers to cloud infrastructure and the chips powering it all. These companies benefit from stable government contracts and increasing federal investment in digital transformation.

3

Why These Stocks

These companies were selected for their established relationships with federal agencies, specialized government-focused solutions, and strategic positioning to capture the growing public sector technology spend. Recent partnerships, like Palantir with Accenture, highlight this accelerating trend.

Why You'll Want to Watch These Stocks

🔐

Government Contracts = Steady Revenue

Federal tech contracts often span multiple years and billions of dollars, providing these companies with predictable, recession-resistant revenue streams that investors love.

🚀

AI Spending Just Getting Started

The government's digital transformation is still in early stages, with analysts forecasting massive spending increases as agencies rush to implement AI and advanced analytics capabilities.

🔄

Palantir's Comeback Story

After a challenging period, Palantir's recent partnership with Accenture signals renewed growth potential in this sector, potentially foreshadowing similar opportunities for other companies in this group.

Get the full story on this Basket. Read our detailed article on its risks and potential.

Read Full Insight

Why Invest with Nemo Money?

Nemo Logo Fade
🆓

Zero Commission

Trade stocks, ETFs, and more with zero commission. Keep more of your returns.

🔒

Trusted & Regulated

Part of Exinity Group 2015, serving over a million customers globally.

💰

6% Interest on Cash

Earn 6% AER on uninvested cash with daily interest payments.

Discover More Opportunities

Beverage Stocks: What's Next After Coca-Cola's Pivot

Beverage Stocks: What's Next After Coca-Cola's Pivot

Coca-Cola is discontinuing its historic Minute Maid frozen products to focus on faster-growing beverage categories. This strategic shift highlights a broader investment opportunity in companies leading the market's transition toward healthier, more convenient, and functional drinks.

Factory Automation Stocks | Rising Labor Costs Trend

Factory Automation Stocks | Rising Labor Costs Trend

Volkswagen's recent agreement with the UAW signals a new era of rising labor costs for foreign automakers in the U.S. This theme focuses on companies poised to benefit as the industry increases investment in factory automation and robotics to enhance productivity.

Blood Thinner Breakthrough Explained | Market Overview

Blood Thinner Breakthrough Explained | Market Overview

Bayer's successful Phase III trial for its new blood thinner has demonstrated a significant reduction in stroke recurrence. This breakthrough positions the company favorably against competitors and highlights an investment opportunity in the evolving landscape of cardiovascular treatments.

Frequently Asked Questions